問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Rheumatology

更新時間:2023-09-19

張詩欣
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

3Cases

2021-06-01 - 2026-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting3Sites

Recruiting7Sites

2021-06-30 - 2024-09-02

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-02-01 - 2019-12-31

Phase III

PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) WITHOUT X-RAY EVIDENCE OF ANKYLOSING SPONDYLITIS (AS) AND OBJECTIVE SIGNS OF INFLAMMATION
  • Condition/Disease

    Active axial spondyloarthritis (axSpA)

  • Test Drug

    Certolizumab Pegol 200mg/ml, solution for subcutaneous injection

Participate Sites
5Sites

Terminated4Sites